Login to Your Account

Financings Roundup

Synageva Adds $25M for SBC-102 Trials, Pipeline

By Tom Wall

Tuesday, March 22, 2011
Privately held Synageva BioPharma Corp. closed a $25 million private equity financing that it said would support an early stage clinical program for lead candidate SBC-102, an enzyme replacement therapy for lysosomal acid lipase (LAL) deficiency, and four preclinical compounds for rare disorders. The Lexington, Mass.-based biotech has raised a total of $70 million since early 2009.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription